Claude Messiaen

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Pierre Quartier, Florence Allantaz, Rolando Cimaz et al. · Annals of the Rheumatic Diseases · 2010 · 549 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +10

Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases

Geneviève Baujat, Rémy Choquet, S. Bouée et al. · Orphanet Journal of Rare Diseases · 2017 · 120 citations · Full text

Medicine, Pathology, Epidemiologic Methods +14

A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research

Rémy Choquet, Meriem Maaroufi, Albane de Carrara et al. · Journal of the American Medical Informatics Association · 2014 · 100 citations · Full text

Computing, Biomedical Informatics, Health Informatics +17

Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study

Johanna Benhamou, D. Gensburger, Claude Messiaen et al. · Journal of Bone and Mineral Research · 2016 · 56 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

The ongoing French BaMaRa-BNDMR cohort: implementation and deployment of a nationwide information system on rare disease

Anne‐Sophie Jannot, Claude Messiaen, Ahlem Khatim et al. · Journal of the American Medical Informatics Association · 2021 · 34 citations · Full text

Computing, Biomedical Informatics, Health Informatics +14